A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes
| 대상 질환 | Type 2 Diabetes Mellitus |
|---|---|
| 임상 단계 | 3상 |
| 스폰서 | Eli Lilly and Company |
| 상태 | 완료 |
| 참여자 수 | 13,299 명 |
| 중재(약물) | Tirzepatide, Dulaglutide |
| 시작일 | 2020년 5월 29일 |
| 완료일 | 2025년 6월 12일 |
| 결과 공개일 | 2026년 7월 8일 |
요약
The purpose of the trial is to assess the efficacy and safety of tirzepatide to dulaglutide in participants with type 2 diabetes and increased cardiovascular risk.
Number of Participants From Randomization to First Occurrence of Death From MACE-3 [Composite Endpoint of Major Adverse Cardiovascular Events Death From Cardiovascular Causes, Myocardial Infarction (MI) or Stroke]
| Tirzepatide (MTD) | 801 participants |
|---|---|
| 1.5 mg Dulaglutide | 862 participants |
BENITIONS에서 보기 ClinicalTrials.gov 원문 보기
같은 질환의 다른 임상
- Cardiovascular Outcomes in Bariatric Surgery Patients With Type 2 Diabetes — The Cleveland Clinic
- Diabetes Prevention Program Outcomes Study — National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- Uric Acid Lowering Trial in Youth Onset T2D — University of Colorado, Denver
- Financial Incentives And Nurse Coaching to Enhance Diabetes Outcomes (FINANCE-DM)-1 — State University of New York at Buffalo
- Continuous Glucose Monitoring Following Hospital Discharge — Kathleen Dungan
- Skeletal Muscle Diacylglycerol and Sphingolipids - Impact of Localization and Species on I — University of Colorado, Denver